IN RE: RISPERDAL / SEROQUEL / ZYPREXA LITIGATION

CIVIL ACTION AUGELESSICAR MARKET

THIS MATTER having come before the court on <u>July 14, 2011</u> concerning the case management of all pending New Jersey state cases in the above-captioned litigation, and good cause having been shown;

IT IS on this 14th day of July, 2011 effective from the conference date:

## **ORDERED** as follows:

- 1. Prior to the next scheduled Case Management conference, plaintiff's counsel shall advise defense counsel as to the availability to depose Megan Finch (L-6669-06) in New Jersey in the Fall of 2011.
- 2. Prior to the next scheduled Case Management Conference, plaintiff's counsel shall advise defense counsel regarding the ability of George Cole (L-6999-06) to appear for a deposition in New Jersey and provide specificity, based upon communications with Mr. Cole's treating doctors, as to when Mr. Cole's deposition may be scheduled.
- 3. Prior to the next scheduled Case Management Conference, plaintiff's counsel shall advise defense counsel as to the status of any appeals regarding the continued commitment of Karl Rupp (L-6934-06).
- 4. Counsel for defendant Janssen shall provide two consecutive deposition dates for the depositions of corporate representatives with relevant knowledge as to the Adverse Events Database in the event that more than one corporate representative is designated as having such knowledge.

5. The next Case Management Conference is scheduled on August 11, 2011 at 1:30 p.m. in courtroom 403. Any joint agenda items and submissions shall be submitted to the court by noon on August 4, 2011.

JESSICA R. MAYER, J.S.C.